share_log

PharmaCielo Q2 Revenue Soars 375% YoY, Raises Additional $4.6M In Oversubscribed Debenture Financing

PharmaCielo Q2 Revenue Soars 375% YoY, Raises Additional $4.6M In Oversubscribed Debenture Financing

PharmaCielo第二季度營收同比飆升375%,額外籌集460萬美元超額認購債券融資
Benzinga Real-time News ·  2022/08/31 08:38
PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) Q2 2022 revenue was CA$2.1 million, a 375% increase compared to CA$446,000 in Q2 2021.
PharmaCielo Ltd.(場外交易:PCLOF)(多倫多證券交易所股票代碼:PCLO)2022年第二季度收入為210萬加元,增長375%相比之下,2021年第二季度為446,000加元。
Q2 2022 Financial Highlights
2022年第二季度財務亮點
Net loss was CA$3.5 million compared to net loss of CA$7.2 million in Q2 2021. Adjusted EBITDA was a loss of CA$2.1 million compared to a loss of CA$4.5 million in Q2 2021. Cash equivalents of CA$1 million at June 30, 2022, compared to CA$5.3 million at December 31, 2021. Gross profit was CA$834,814 compared to a loss of CA$807,700 in Q2 2021.
淨虧損為350萬加元相比之下,2021年第二季度淨虧損為720萬加元。 調整後的EBITDA虧損210萬加元相比之下,2021年第二季度虧損450萬加元。 C100萬加元的灰當量截至2022年6月30日,與2021年12月31日的530萬加元相比。 毛利潤為加元834,814相比之下,2021年第二季度虧損807,700加元。
Bill Petron, chairman and CEO of PharmaCielo stated, "The team has made substantial progress in the first six months of the year. We continue to build the revenue line...
比爾·彼得龍,PharmaCielo董事長兼首席執行官表示...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論